Innate immunity in breast carcinoma

Endocrine-Related Cancer

Volumn 10, Issue 2, 2003, Pages 301-308

  Sfondrini, L ^a   Balsari, A ^b   Menard S ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CYCLOSPORIN A; CYTOSINE; DINUCLEOTIDE; GUANOSINE; MYCOBACTERIUM ANTIGEN; OLIGONUCLEOTIDE; PATTERN RECOGNITION RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; BREAST CARCINOMA; CANCER PATIENT; CONTROLLED STUDY; CPG ISLAND; HIGH RISK PATIENT; IMMUNE RESPONSE; IMMUNE SYSTEM; METHYLATION; MOUSE; NONHUMAN; PROTEIN MOTIF; REVIEW; TUMOR IMMUNITY;

ANIMALS; BREAST NEOPLASMS; HUMANS; IMMUNITY, NATURAL;

EID: 0037599493     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0100301     Document Type: Review

References (98)

1. Aisner J, Weinberg V, Perloff M, Weiss R, Perry M, Korzun A, Ginsberg S & Holland JF 1987 Chemotherapy versus chemoimmunotherapy (CAF v CAFVP v CMF each +/- MER) for metastatic carcinoma of the breast: a CALGB study. Cancer and Leukemia Group B. Journal of Clinical Oncology 5 1523-1533.
2. Akira S, Takeda K & Kaisho T 2001 Toll-like receptors: critical proteins linking innate and acquired immunity. Nature Immunology 2 675-680.
3. Aliprantis AO, Yang RB, Mark MR, Suggett S, Devaux B, Radolf JD, Klimpel GR, Godowski P & Zychlinsky A 1999 Cell activation and apoptosis by bacterial lipoproteins through toll-like receptor-2. Science 285 736-739.
4. Audibert F, Chedid L, Lefrancier P, Choay J & Lederer E 1977 Relationship between chemical structure and adjuvant activity of some synthetic analogues of N-acetyl-muramyl-1-alanyl-d-isoglutamine (MDP). Annals of Immunology 128C 653-661.
5. Ballas ZK, Rasmussen WL & Krieg AM 1996 Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. Journal of Immunology 157 1840-1845.
6. Ballas ZK, Krieg AM, Warren T, Rasmussen W, Davis HL, Waldschmidt M & Weiner GJ 2001 Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. Journal of Immunology 167 4878-4886.
7. Blazar BR, Krieg AM & Taylor PA 2001 Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. Blood 98 1217-1225.
8. Boggio K, Nicoletti G, Di Carlo E, Cavallo F, Landuzzi L, Melani C, Giovarelli M, Rossi I, Nanni P, De Giovanni C, Bouchard P, Wolf S, Modesti A, Musiani P, Lollini PL, Colombo MP & Forni G 1998 Interleukin 12-mediated prevention of spontaneous mammary adenocarcinomas in two lines of Her-2/neu transgenic mice. Journal of Experimental Medicine 188 589-596.
9. Bretscher PA 1992 A strategy to improve the efficacy of vaccination against tubercolosis and leprosy. Immunology Today 13 342-345.
10. Brightbill HD, Libraty DH, Krutzik SR, Yang RB, Belisle JT, Bleharski JR, Maitland M, Norgard MV, Plevy SE, Smale ST, Brennan PJ, Bloom BR, Godowski PJ & Modlin RL 1999 Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science 285 732-736.
11. Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R & Gehan EA 1986 Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. National Cancer Institute Monographs 1 81-85.
12. Carpentier AF, Chen L, Maltonti F & Delattre JY 1999 Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Research 59 5429-5432.
13. Carpentier AF, Xie J, Mokhtari K & Delattre JY 2000 Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clinical Cancer Research 6 2469-2473.
14. Chu RS, Targoni OS, Krieg AM, Lehmann PV & Harding CV 1997 CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. Journal of Experimental Medicine 186 1623-1631.
15. Crispen R 1989 History of BCG and its substrains. Progress in Clinical Biological Research 310 35-50.
16. Crowe JP Jr, Gordon NH, Shenk RR, Soegiarso RW, Hubay CA, Mansour EG, Shuck JM, Pearson OH, Marshall JS & Arafah B 1990 Short-term tamoxifen plus chemotherapy: superior results in node-positive breast cancer. Surgery 108 619-627.
17. Curran EM, Berghaus LJ, Vernetti NJ, Saporita AJ, Lubahn DB & Estes DM 2001 Natural killer cells express estrogen receptor-alpha and estrogen receptor-beta and can respond to estrogen via a non-estrogen receptor-alpha-mediated pathway. Cellular Immunology 214 12-20.
18. Davila E & Celis E 2000 Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. Journal of Immunology 165 539-547.
19. Dow SW, Fradkin LG, Liggitt DH, Willson AP, Heath TD & Potter TA 1999 Lipid-DNA complexes induce potent activation of innate immune responses and antitumor activity when administered intravenously. Journal of Immunology 163 1552-1561.
20. Early Breast Cancer Trialists' Group 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women. Lancet 339 1-15.
21. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L & Wolmark N 1998 Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. Journal of the National Cancer Institute 90 1371-1388.
22. Flynn JL & Ernst JD 2000 Immune responses in tuberculosis. Current Opinion in Immunology 12 432-436.
23. Flynn JL & Chan J 2001 Immunology of tuberculosis. Annual Review of Immunology 19 93-129.
24. Gaylord H & Brennan PJ 1987 Leprosy and the leprosy bacillus: recent developments in characterization of antigens and immunology of the disease. Annual Review of Microbiology 41 645-675.
25. Gazit Z & Kedar E 1994 Chemotherapy-induced modulation of natural killer and lymphokine-activated killer cell activity in euthymic and athymic mice. Cancer Immunology Immunotherapy 38 243-252.
26. Giuliano AE, Sparks FC, Patterson K, Spears I & Morton DL 1986 Adjuvant chemo-immunotherapy in stage II carcinoma of the breast. Journal of Surgical Oncology 31 255-259.
27. Glover JM, Leeds JM, Mant TG, Amin D, Kisner DL, Zuckerman JE, Geary RS, Levin AA & Shanahan WR Jr 1997 Phase I safety and pharmacokinetic profile of an intercellular adhesion molecule-1 antisense oligodeoxynucleotide (ISIS 2302). Journal of Pharmacology and Experimental Therapeutics 282 1173-1180.
28. Gorter A & Meri S 1999 Immune evasion of tumor cells using membrane-bound complement regulatory proteins. Immunology Today 20 576-582.
29. Grange JM & Stanford JL 1990 BCG vaccination and cancer. Tubercle 71 61-64.
30. Grange JM, Stanford JL & Rook GAW 1995 Tuberculosis and cancer: parallels in host responses and therapeutic approaches? Lancet 345 1350-1352.
31. Groopman JE 1987 Neoplasms in the acquired immune deficiency syndrome: the multidisciplinary approach to treatment. Seminars in Oncology 14 1-6.
32. Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD & Muller WJ 1992 Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. PNAS 89 10578-10582.
33. Hafner M, Zawatzky R, Hirtreiter C, Buurman WA, Echtenacher B, Hehlgans T & Mannel DN 2001 Antimetastatic effect of CpG DNA mediated by type I IFN. Cancer Research 61 5523-5528.
34. Hartmann G, Weiner GJ & Krieg AM 1999 CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. PNAS 96 9305-9310.
35. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, Eng JK, Akira S, Underhill DM & Aderem A 2001 The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 410 1099-1103.
36. Heckelsmiller K, Rall K, Beck S, Schlamp A, Seiderer J, Jahrsdorfer B, Krug A, Rothenfusser S, Endres S & Hartmann G 2002 Peritumoral CpG DNA elicits a coordinated response of CD8 T cells and innate effectors to cure established tumors in a murine colon carcinoma model. Journal of Immunology 169 3892-3899.
37. Heldwein KA & Fenton MJ 2002 The role of Toll-like receptors in immunity against mycobacterial infection. Microbes Infection 4 937-944.
38. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K & Akira S 2000 A Toll-like receptor recognizes bacterial DNA. Nature 408 740-745.
39. Jakob T, Walker PS, Krieg AM, Udey MC & Vogel JC 1998 Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. Journal of Immunology 161 3042-3049.
40. Jurianz K, Ziegler S, Garcia-Schuler H, Kraus S, Bohana-Kashtan O, Fishelson Z & Kirschfink M 1999 Complement resistance of tumor cells: basal and induced mechanisms. Molecular Immunology 36 929-939.
41. Kalland T & Forsberg JG 1981 Natural killer cell activity and tumor susceptibility in female mice treated neonatally with diethylstilbestrol. Cancer Research 41 5134-5140.
42. Kawarada Y, Ganss R, Garbi N, Sacher T, Arnold B & Hammerling GJ 2001 NK- and CD8(+) T cell-mediated eradication of established tumors by peritumoral injection of CPG-containing oligodeoxynucleotides. Journal of Immunology 167 5247-5253.
43. Kawasaki K, Akashi S, Shimazu R, Yoshida T, Miyake K & Nishijima M 2000 Mouse toll-like receptor 4.MD-2 complex mediates lipopolysaccharide-mimetic signal transduction by Taxol. Journal of Biological Chemistry 275 2251-2254.
44. Khong HT & Restifo NP 2002 Natural selection of tumor variants in the generation of 'tumor escape' phenotypes. Nature Immunology 3 999-1005.
45. Kim SK, Ragupathi G, Musselli C, Choi SJ, Park YS & Livingston PO 1999 Comparison of the effect of different immunological adjuvants on the antibody and T-cell response to immunization with MUC1-KLH and GD3-KLH conjugate cancer vaccines. Vaccine 18 597-603.
46. Kim SK, Ragupathi G, Cappello S, Kagan E & Livingston PO 2000 Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates, Vaccine 19 530-537.
47. Krieg AM 2002 CpG motifs in bacterial DNA and their immune effects. Annual Review of Immunology 20 709-760.
48. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA & Klinman DM 1995 CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374 546-549.
49. Kurt-Jones EA, Popova L, Kwinn L, Haynes LM, Jones LP, Tripp RA, Walsh EE, Freeman MW, Golenbock DT, Anderson LJ & Finberg RW 2000 Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nature Immunology 1 398-401.
50. Kurzawa H, Wysocka M, Aruga E, Chang AE, Trinchieri G & Lee WM 1998 Recombinant interleukin 12 enhances cellular immune responses to vaccination only after a period of suppression. Cancer Research 58 491-499.
51. Lamm DL, Thor DE, Harris SC, Reyna JA, Stogdill VD & Radwin HM 1980 Bacillus Calmette-Guerin immunotherapy of superficial bladder cancer. Journal of Urology 124 38-40.
52. Lanuti M, Rudginsky S, Force SD, Lambright ES, Siders WM, Chang MY, Amin KM, Kaiser LR, Scheule RK & Albelda SM 2000 Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models. Cancer Research 60 2955-2963.
53. Lemaitre B, Nicolas E, Michaut L, Reichhart JM & Hoffmann JA 1996 The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 973-983.
54. Likhite VV 1976 Experimental cancer immunotherapy: comparison of tumor rejection if F344 rats given live Mycobacterium bovis (Strain BCG) and killed Corynebacterium parvum. Journal of the National Cancer Institute 56 985-989.
55. Lipford GB, Sparwasser T, Bauer M, Zimmermann S, Koch ES, Heeg K & Wagner H 1997 Immunostimulatory DNA: sequence-dependent production of potentially harmful or useful cytokines. European Journal of Immunology 27 3420-3426.
56. Maes H & Cocito C 1996 Cancer prevention by adoptive transfer of antigen 60-activated immunocompetent cells. Scandinavian Journal of Immunology 43 283-288.
57. Maes H, Taper H & Cocito C 1995 Alteration of the immune response during cancer development and prevention by administration of a mycobacterial antigen. Scandinavian Journal of Immunology 41 53-64.
58. Marincola FM, Jaffee EM, Hicklin DJ & Ferrone S 2000 Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Advances in Immunology 74 181-273.
59. Marshall JS, Gordon NH, Hubay CA & Pearson OH 1987 Assessment of tamoxifen as adjuvant therapy in stage II breast cancer: a long-term follow-up. Journal of Laboratory and Clinical Medicine 109 300-307.
60. Martino A, Vismara D, Cicconi R, Delpino A, Ivanyi J, Colizzi V, Cassol M, Fraziano M & Piselli P 2001 Effective anti-tumor immunity induced in mice by a two-step vaccination protocol. In Vivo 15 425-428.
61. Means TK, Lien E, Yoshimura A, Wang S, Golenbock DT & Fenton MJ 1999 The CD14 ligands lipoarabinomannan and lipopolysaccharide differ in their requirement for Toll-like receptors. Journal of Immunology 163 6748-6755.
62. Medzhitov R 2001 Toll-like receptors and innate immunity. Nature Reviews Immunology 1 135-145.
63. Medzhitov R & Janeway CJ 2000 The Toll receptor family and microbial recognition. Trends in Microbiology 8 452-456.
64. Medzhitov R, Preston-Hurlburt P & Janeway CA Jr 1997 A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 394-397.
65. van der Meijden AP, Debruyne FM, Steerenberg PA & De Jong WH 1989 Aspects of non-specific immunotherapy with BCG in superficial bladder cancer: an overview. Progress in Clinical and Biological Research 310 11-33.
66. Miconnet I, Koenig S, Speiser D, Krieg A, Guillaume P, Cerottini JC & Romero P 2002 CpG are efficient adjuvants for specific CTL induction against tumor antigen-derived peptide. Journal of Immunology 168 1212-1218.
67. Morales A, Eidinger D & Bruce AW 1976 Intracavitary bacillus Calmette-Guerin in the treatment of superficial bladder tumors. Journal of Urology 116 180-183.
68. Nauts HC 1980 The beneficial effects of bacterial infections on host resistence to cancer. End results in 449 cases. Cancer Research Institute Monograph 18.
69. Nauts HC 1989 Bacteria and cancer - antagonisms and benefits. Cancer Surveys 8 713-723.
70. Saha K, Kapila H, Madan R & Shinghal RN 1986 Immunologic tools to decipher efficacy of BCG immunotherapy in advanced breast cancer: a one year follow up study. Asian Pacific Journal of Allergy and Immunology 4 139-148.
71. Schwandner R, Dziarski R, Wesche H, Rothe M & Kirschning CJ 1999 Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. Journal of Biological Chemistry 274 17406-17409.
72. Seaman WE, Blackman MA, Gindhart TD, Roubinian JR, Loeb JM & Talal N 1978 β-Estradiol reduces natural killer cells in mice. Journal of Immunology 121 2193-2198.
73. Senn HJ, Amgwerd R, Jungi WF, Hochuli R, Ammann J, Engelhart G, Heinz C, Wick A, Enderlin F, Creux G, Simon B, Lanz R, Bigler R & Seiler S 1982 Adjuvant chemoimmunotherapy with LMF plus BCG in node-negative and node-positive breast cancer - intermediate report at 4 years. Recent Results in Cancer Research 80 177-184.
74. Serrou B, Sancho-Garnier H, Cappelaere P, Plagne R, Metz R, Schneider M, Chollet P, Namer N, Pujol H, Gary-Bobo J, Meyer G & Mathe G 1982 Follow-up results from a randomized trial for T3 and T4 breast cancer patients: previous BCG immunotherapy improves response to chemotherapy in the relapse patient. Recent Results in Cancer Research 80 157-161.
75. Sfondrini L, Rodolfo M, Singh M, Colombo MP, Colnaghi MI, Mnard S & Balsari A 2000 Cooperative effects of Mycobacterium tuberculosis Ag38 gene transduction and IL-12 in vaccination against spontaneous tumor development in proto-neu-transgenic mice. Cancer Research 60 3777-3781.
76. Sfondrini L, Besusso D, Rumio C, Rodolfo M, Mnard S & Balsari A 2002a Prevention of spontaneous mammary adenocarcinoma in HER-2/neu transgenic mice by foreign DNA. FASEB Journal 16 1749-1754.
77. Sfondrini L, Besusso D, Zoia MT, Rodolfo M, Invernizzi AM, Taniguchi M, Nakayama T, Colombo MP, Mnard S & Balsari A 2002b Absence of CD1 molecule up-regulates antitumor activity induced by CpG oligodeoxynucleotides in mice. Journal of Immunology 169 151-158.
78. Smith JB & Wickstrom E 1998 Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model. Journal of the National Cancer Institute 90 1146-1154.
79. Smyth MJ, Taniguchi M & Street SE 2000 The anti-tumor activity of IL-12: mechanisms of innate immunity that are model and dose dependent. Journal of Immunology 165 2665-2670.
80. Sparwasser T, Koch ES, Vabulas RM, Heeg K, Lipford GB, Ellwart JW & Wagner H 1998 Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. European Journal of Immunology 28 2045-2054.
81. Stein D, Roth S, Vogelsang E & Nusslein-Volhard C 1991 The polarity of the dorsoventral axis in the Drosophila embryo is defined by an extracellular signal. Cell 65 725-735.
82. Stenger S & Modlin RL 2002 Control of Mycobacterium tuberculosis through mammalian Toll-like receptors. Current Opinion in Immunology 14 452-457.
83. Stewart T, Tsai SC, Grayson H, Henderson R & Opelz G 1995 Incidence of de-novo breast cancer in women chronically immunosuppressed after organ transplantation. Lancet 346 796-798.
84. Takeuchi O, Hoshino K, Kawai T, Sanjo H, Takada H, Ogawa T, Takeda K & Akira S 1999 Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 11 443-451.
85. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, Muhlradt PF & Akira S 2000 Cutting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide macrophage-activating lipopeptide-2 activates immune cells through a toll-like receptor 2- and MyD88-dependent signaling pathway. Journal of Immunology 164 554-557.
86. Taniguchi F, Yamagishi H, Fujiwara H, Ueda Y, Fuji N, Yoshimura T & Oka T 1998 Systemic administration of rIL-12 synergistically enhances the therapeutic effect of a TNF gene-transduced cancer vaccine. Gene Therapy 5 1677-1684.
87. Thoma-Uszynski S, Stenger S, Takeuchi O, Ochoa MT, Engele M, Sieling PA, Barnes PF, Rollinghoff M, Bolcskei PL, Wagner M, Akira S, Norgard MV, Belisle JT, Godowski PJ, Bloom BR & Modlin RL 2001 Induction of direct antimicrobial activity through mammalian toll-like receptors. Science 291 1544-1547.
88. Tokunaga T, Yamamoto H, Shimada S, Abe H, Fukuda T, Fujisawa Y, Furutani Y, Yano O, Kataoka T & Sudo T 1984 Antitumor activity of deoxyribonucleic acid fraction from Mycobacterium bovis BCG. I. Isolation, physicochemical characterization, and antitumor activity. Journal of the National Cancer Institute 72 955-962.
89. Tzai TS, Lin JS & Chow NH 1996 Modulation of antitumor immunity of tumor-bearing mice with low-dose cyclophosphamide. Journal of Surgical Research 65 139-144.
90. Underhill DM, Ozinsky A, Hajjar AM, Stevens A, Wilson CB, Bassetti M & Aderem A 1999a The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401 811-815.
91. Underhill DM, Ozinsky A, Smith KD & Aderem A 1999b Toll-like receptor-2 mediates mycobacteria-induced proinflammatory signaling in macrophages. PNAS 96 14459-14463.
92. Vaage J 1983 Mammary tumor growth inhibition in C3H/He mice by long-term bacillus Calmette-Guerin immunoprophylaxis versus enhancement by primary bacillus Calmette-Guerin therapy. Cancer Research 43 5778-5782.
93. Warren TL, Dahle CE & Weiner GJ 2000 CpG oligodeoxynucleotides enhance monoclonal antibody therapy of a murine lymphoma. Clinical Lymphoma 1 57-61.
94. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE & Krieg AM 1997 Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. PNAS 94 10833-10837.
95. Weinstein SP, Orel SG, Collazzo L, Conant EF, Lawton TJ & Czerniecki B 2001 Cyclosporin A-induced fibroadenomas of the breast: report of five cases. Radiology 220 465-468.
96. Wickstrom E 1997 Antisense c-myc inhibition of lymphoma growth. Antisense and Nucleic Acid Drug Development 7 225-228.
97. Yamamura Y, Azuma I, Taniyama T, Sugimura K, Hirao F, Tokuzen R, Okabe M, Nakahara W, Yasumoto K & Ohta M 1976 Immunotherapy of cancer with cell wall skeleton of Myocabacterium bovis-bacillus Calmette-Guerin: experimental and clinical results. Annals of the New York Academy of Sciences 277 209-227.
98. Yron I, Cohen D, Robinson E, Haber M & Weiss DW 1975 Effects of methanol extraction residue and therapeutic irradiation against established isografts and simulated local recurrence of mammary carcinomas. Cancer Research 35 1779-1790.